P/E at 33.48 vs Industry's 31.18: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Amidst Sector Norms

The current P/E of Sun Pharmaceutical Industries Ltd stands at 33.48, compared to the Pharmaceuticals & Biotechnology industry average of 31.18. This 7.4% premium suggests that the market is pricing in expectations of relatively stronger earnings growth or superior business fundamentals. However, the premium is not excessive, indicating a balanced valuation stance rather than an overheated one. Investors might wonder previously rated Hold, what is Sun Pharma’s current rating? The valuation premium is a key factor in this reassessment.

Performance Across Timeframes: Divergent Momentum

Examining the stock’s returns reveals a nuanced picture. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a modest gain of 1.15%, outperforming the Sensex’s 0.43% rise. This outperformance, though slight, indicates resilience over a longer horizon. Yet, the shorter-term data tells a different story. The three-month return is down 5.32%, while the Sensex has declined by a more severe 13.55%, showing relative strength in the medium term. Year-to-date, the stock is down 1.87%, significantly outperforming the Sensex’s 13.81% fall. This contrast between short and medium-term performance raises the question is this a temporary setback or a sign of shifting fundamentals?

Shorter intervals also show mixed results. The one-month return is -6.19%, slightly better than the sector’s -6.93%, while the one-week return is -3.97%, underperforming the Sensex’s 2.09% gain. The stock’s one-day performance was a decline of 0.39%, yet it outperformed the Sensex’s 0.88% drop, suggesting some defensive qualities in volatile sessions.

Moving Average Configuration: Signs of a Complex Trend

The technical setup of Sun Pharmaceutical Industries Ltd offers further insight. The stock currently trades above its 200-day moving average, a long-term bullish indicator, but remains below its 5, 20, 50, and 100-day moving averages. This configuration suggests a recent recovery attempt within a broader consolidation or correction phase. The stock has just ended a four-day losing streak with a gain, hinting at potential short-term support. The 200-day average acting as a floor may be a critical level to watch, but the failure to clear shorter-term averages indicates resistance remains. The 5% surge partially reverses a 6.19% monthly decline — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Sector Performance Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has experienced a varied performance landscape recently. While some companies have posted gains, others have faced headwinds from regulatory pressures and pricing challenges. Within this context, Sun Pharmaceutical Industries Ltd’s relative outperformance over three months and year-to-date is notable. The sector’s average P/E of 31.18 reflects moderate valuation levels, with should investors in Sun Pharma hold, buy more, or reconsider? The current rating provides the answer.

Rating Reassessment: From Hold to Buy

On 23 Feb 2026, the rating for Sun Pharmaceutical Industries Ltd was updated from Hold to a new assessment. This change reflects a comprehensive review of valuation, performance, and technical indicators. The previous Mojo Score was 72.0, signalling a solid foundation for the reassessment. The rating update aligns with the stock’s ability to outperform the Sensex over one year and maintain relative strength in a challenging sector environment. The valuation premium and moving average configuration were key inputs in this decision, underscoring the importance of multi-dimensional analysis.

Market Capitalisation and Trading Dynamics

With a market capitalisation of ₹4,04,911.77 crores, Sun Pharmaceutical Industries Ltd firmly holds its place as a large-cap stock within the Pharmaceuticals & Biotechnology sector. The stock opened at ₹1698.3 today and has traded around this level, showing limited intraday volatility. Despite a slight decline of 0.39% on the day, it outperformed the Sensex’s 0.88% fall, indicating relative defensive qualities. The recent gain after four consecutive days of losses may signal a short-term technical rebound, but the broader trend remains under scrutiny.

Long-Term Performance: A Mixed Decade

Over a 10-year horizon, Sun Pharmaceutical Industries Ltd has delivered a total return of 107.72%, lagging behind the Sensex’s 197.55% gain. However, the stock’s 5-year return of 171.84% significantly outpaces the Sensex’s 47.90%, highlighting a strong medium-term rally. The 3-year return of 66.80% also exceeds the Sensex’s 22.76%, reinforcing the stock’s ability to generate alpha in recent years. This divergence between medium and long-term returns invites the question does this reflect a structural shift or cyclical recovery?

Conclusion: A Balanced View from Data

The data on Sun Pharmaceutical Industries Ltd paints a picture of a stock trading at a modest premium to its sector, with mixed but generally resilient performance across multiple timeframes. The moving average configuration suggests a tentative recovery within a longer-term consolidation phase. The rating reassessment from Hold to a more positive stance reflects these nuanced dynamics. Investors analysing this stock must weigh the valuation premium against recent momentum shifts and sector conditions — what is the current rating for Sun Pharma, and how should it influence portfolio decisions?

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today